Digestive Health & Gastroenterology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

This Phase 3 trial is testing vedolizumab, a biologic medicine, in children and teenagers with moderate to severe ulcerative colitis or Crohn's disease. The study focuses on giving the drug through a subcutaneous injection, which is a shot under the skin. This method could make treatment easier and more convenient compared to intravenous infusions. The trial is recruiting participants from around the world and will follow them for up to 34 weeks to observe the drug’s effects.

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

This Phase 3 study is also testing vedolizumab but given by intravenous infusion to children and teenagers with moderate to severe Crohn's disease. The goal is to find out if this treatment can maintain remission and reduce inflammation over a longer period, measured after 54 weeks. If successful, it could provide an important treatment option to help young patients manage their symptoms and improve quality of life.

Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization

This study is exploring whether sending text messages can encourage more adults to complete colorectal cancer screening tests at home. The research is taking place in community health centers across multiple locations in the United States. If the text message program works, it could make it easier for people to get screened early, which is key to preventing and treating colorectal cancer successfully.

Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease

This Phase 4 study is looking at how safe and effective adalimumab injections are for children aged 6 years and older who have moderate to severe active Crohn's disease. By collecting data over a year from 30 children, the study hopes to provide more information about this treatment’s benefits and risks in young patients. This could help doctors and families make better decisions about managing Crohn's disease in children.

A Prospective Evaluation of Non-Operative Treatments for Gastrocutaneous Fistulae in Children

This Phase 4 study is testing non-surgical ways to treat gastrocutaneous fistulae, which are complications sometimes occurring after gastrostomy tube removal in children. If these less invasive treatments are effective, they may reduce the need for surgery, helping children recover more comfortably. The study enrolled 100 children and is gathering results to see how well these approaches work.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.